GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (STU:698) » Definitions » Current Accrued Expense

Achilles Therapeutics (STU:698) Current Accrued Expense : €3.97 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Current Accrued Expense?

Achilles Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2024 was €3.97 Mil.

Achilles Therapeutics's quarterly Current Accrued Expense declined from Sep. 2023 (€4.35 Mil) to Dec. 2023 (€3.69 Mil) but then increased from Dec. 2023 (€3.69 Mil) to Mar. 2024 (€3.97 Mil).

Achilles Therapeutics's annual Current Accrued Expense declined from Dec. 2021 (€6.19 Mil) to Dec. 2022 (€3.88 Mil) and declined from Dec. 2022 (€3.88 Mil) to Dec. 2023 (€3.69 Mil).


Achilles Therapeutics Current Accrued Expense Historical Data

The historical data trend for Achilles Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Current Accrued Expense Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
0.81 3.78 6.19 3.88 3.69

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.56 6.99 4.35 3.69 3.97

Achilles Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Achilles Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Achilles Therapeutics (STU:698) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (STU:698) Headlines

No Headlines